title: Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes.
abstract: We investigated HIV-1 vaccine-induced lymphoproliferative responses in healthy volunteers immunized intradermally or intramuscularly (with or without adjuvant granulocyte-macrophage colony-stimulating factor [GM-CSF] protein) with DNA expressing HIV-1 gag, env, rev, and rt at months 0, 1, and 3 using a Biojector and boosted at 9 months with modified vaccinia virus Ankara (MVA) expressing heterologous HIV-1 gag, env, and pol (HIV-MVA). Lymphoproliferative responses to aldrithiol-2 (AT-2)-inactivated-HIV-1 antigen were tested by a [(3)H]thymidine uptake assay and a flow-cytometric assay of specific cell-mediated immune response in activated whole blood (FASCIA-WB) 2 weeks after the HIV-MVA boost (n = 38). A FASCIA using peripheral blood mononuclear cells (FASCIA-PBMC) was also employed (n = 14). Thirty-five of 38 (92%) vaccinees were reactive by the [(3)H]thymidine uptake assay. Thirty-two of 38 (84%) vaccinees were reactive by the CD4(+) T-cell FASCIA-WB, and 7 of 38 (18%) also exhibited CD8(+) T-cell responses. There was strong correlation between the proliferative responses measured by the [(3)H]thymidine uptake assay and CD4(+) T-cell FASCIA-WB (r = 0.68; P < 0.01). Fourteen vaccinees were analyzed using all three assays. Ten of 14 (71%) and 11/14 (79%) demonstrated CD4(+) T-cell responses in FASCIA-WB and FASCIA-PBMC, respectively. CD8(+) T-cell reactivity was observed in 3/14 (21%) and 7/14 (50%) using the FASCIA-WB and FASCIA-PBMC, respectively. All 14 were reactive by the [(3)H]thymidine uptake assay. The overall HIV-specific T-cell proliferative response in the vaccinees employing any of the assays was 100% (38/38). A standardized FASCIA-PBMC, which allows simultaneous phenotyping, may be an option to the [(3)H]thymidine uptake assay for assessment of vaccine-induced T-cell proliferation, especially in isotope-restricted settings.
authors.affiliation: Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden.
authors.forename: Said
authors.initials: S
authors.lastname: Aboud
authors.forename: Charlotta
authors.initials: C
authors.lastname: Nilsson
authors.forename: Katarina
authors.initials: K
authors.lastname: Karlén
authors.forename: Mary
authors.initials: M
authors.lastname: Marovich
authors.forename: Britta
authors.initials: B
authors.lastname: Wahren
authors.forename: Eric
authors.initials: E
authors.lastname: Sandström
authors.forename: Hans
authors.initials: H
authors.lastname: Gaines
authors.forename: Gunnel
authors.initials: G
authors.lastname: Biberfeld
authors.forename: Karina
authors.initials: K
authors.lastname: Godoy-Ramirez
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology* / Q000494:pharmacology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D049109:Cell Proliferation / Q000187:drug effects*; D004279:DNA, Viral / Q000008:administration & dosage; D005434:Flow Cytometry; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007114:Immunization / Q000379:methods*; D014616:Vaccinia virus / Q000235:genetics
chemical_list: D016915:AIDS Vaccines; D004279:DNA, Viral; D016178:Granulocyte-Macrophage Colony-Stimulating Factor
references.citation: Immunol Cell Biol. 1999 Dec;77(6):509-15
references.pmid: 10571671
references.citation: J Immunol. 2008 May 1;180(9):5907-15
references.pmid: 18424710
references.citation: Tumour Biol. 1998;19(3):196-204
references.pmid: 9591046
references.citation: Curr Protoc Immunol. 2001 May;Chapter 7:7.10.1-7.10.10
references.pmid: 18432824
references.citation: J Virol. 1998 Oct;72(10):7992-8001
references.pmid: 9733838
references.citation: J Infect Dis. 2008 Nov 15;198(10):1482-90
references.pmid: 18808335
references.citation: AIDS Res Hum Retroviruses. 2007 Apr;23(4):532-42
references.pmid: 17506610
references.citation: Immunol Cell Biol. 1999 Dec;77(6):559-64
references.pmid: 10571678
references.citation: J Immunol Methods. 1997 Oct 13;208(1):49-59
references.pmid: 9433460
references.citation: AIDS Res Hum Retroviruses. 1998 Jun;14 Suppl 2:S161-6
references.pmid: 9672234
references.citation: AIDS. 2008 Mar 30;22(6):727-35
references.pmid: 18356602
references.citation: Eur J Immunol. 1991 Jun;21(6):1345-9
references.pmid: 1845391
references.citation: Curr Opin HIV AIDS. 2008 May;3(3):349-55
references.pmid: 19372989
references.citation: AIDS. 1990;4 Suppl 1:S201-6
references.pmid: 2152568
references.citation: J Virol. 1987 Jun;61(6):2017-23
references.pmid: 3033328
references.citation: Clin Exp Immunol. 1979 Sep;37(3):551-7
references.pmid: 315848
references.citation: J Virol. 2007 Jan;81(1):434-8
references.pmid: 17050606
references.citation: J Exp Med. 2008 Jan 21;205(1):63-77
references.pmid: 18195071
references.citation: J Immunol Methods. 1996 Sep 9;195(1-2):63-72
references.pmid: 8814321
references.citation: Eur J Immunol. 1994 Jan;24(1):34-40
references.pmid: 8020568
references.citation: J Virol. 2006 May;80(10):4717-28
references.pmid: 16641265
references.citation: J Immunol Methods. 2003 Jun 1;277(1-2):17-25
references.pmid: 12799036
references.citation: Nat Immunol. 2002 Nov;3(11):1061-8
references.pmid: 12368910
references.citation: Science. 1997 Nov 21;278(5342):1447-50
references.pmid: 9367954
references.citation: J Immunol. 2006 Nov 15;177(10):7406-15
references.pmid: 17082660